Navigation Links
Two Targeted Therapies Likely Better Than One in Patients with Aggressive Lymphoma, Mayo Clinic Researchers Say
Date:5/18/2009

ORLANDO, Fla., May 18 /PRNewswire-USNewswire/ -- When combined with a cocktail of chemotherapy drugs, two monoclonal antibodies, instead of one, appear to offer superior results in patients with diffuse large B-cell lymphoma, according to Mayo Clinic researchers working with the North Central Cancer Treatment Group (NCCTG).

At the annual meeting of the American Society of Clinical Oncology (ASCO), researchers say that adding the targeted therapy epratuzumab to a regimen known as R-CHOP resulted in an overall 12-month survival of 88 percent in 78 patients. While they call that a very good outcome, the researchers were especially encouraged because the survival rate was 85 percent in patients with high-risk disease.

"These results are very good and very promising, and hopefully will be an important advance over treatment now being offered to patients with this cancer," says the study's lead author, Ivana Micallef, M.D., a Mayo Clinic hematologist. "But we cannot yet say that is so, since the two different regimens haven't been tested head to head."

"Still, we are eager to do a randomized, phase III study because when we compare our results to some other studies of R-CHOP, our findings do look better," she says. In general, those studies showed a 12-month progression-free survival (PFS) of 67 to 79 percent.

The NCCTG multi-institutional research network is planning a clinical trial that will randomize patients with high-risk diffuse large B-cell lymphoma to either this regimen, known as ER-CHOP, or to R-CHOP, the standard treatment. R-CHOP includes a combination of chemotherapy drugs (cyclophosphamide, doxorubicin, and vincristine), the steroid drug prednisone, and rituximab, a monoclonal antibody.

Diffuse large B-cell lymphoma is one of the most common and aggressive forms of non-Hodgkin lymphoma, a cancer of the B-lymphocyte white blood cells.

The researchers are the first to study the addition of epratuzumab to R-CHOP in newly diagnosed, untreated patients. Both epratuzumab and rituximab are monoclonal antibodies that attach to proteins commonly found on the outside surface of B cells -- CD20 for rituximab and CD22 for epratuzumab. They are also used as immunosuppressive agents to treat certain autoimmune diseases where B cells produce antibodies that attack a person's own cells. "These drugs are designed to shut down B cells, whether they are involved in autoimmunity or are malignant," Dr. Micallef says.

Rituximab is approved for use by the Food and Drug Administration, while epratuzumab is not. That means ER-CHOP treatment cannot be used outside of a clinical trial.

In addition to the results on overall survival, the researchers found an 82 percent progression-free survival in the group. The 39 high-risk patients had a 77 percent PFS, and, for the 39 low-risk patients, PFS was 88 percent. Patients are deemed high risk if they have three or more poor prognostic factors, such as age (60 years or older), elevated LDH (a blood test), advanced disease stage, disease outside of lymph nodes and poor physical performance status.

Dr. Micallef says that the treatment, which is given every 21 days, was well tolerated by patients.

The study drug, epratuzumab, was provided by Immunomedics, Inc. The research was funded by NCCTG, a national clinical research group based at Mayo Clinic and sponsored by the National Cancer Institute. NCCTG consists of a network of cancer specialists at community clinics, hospitals and medical centers in the United States, Canada and Mexico.

About Mayo Clinic

Mayo Clinic is the first and largest integrated, not-for-profit group practice in the world. Doctors from every medical specialty work together to care for patients, joined by common systems and a philosophy of "the needs of the patient come first." More than 3,300 physicians, scientists and researchers and 46,000 allied health staff work at Mayo Clinic, which has sites in Rochester, Minn., Jacksonville, Fla., and Scottsdale/Phoenix, Ariz. Collectively, the three locations treat more than half a million people each year. To obtain the latest news releases from Mayo Clinic, go to www.mayoclinic.org/news. For information about research and education, visit www.mayo.edu. MayoClinic.com (www.mayoclinic.com) is available as a resource for your health stories.

VIDEO ALERT: Additional audio and video resources, including excerpts from an interview with Dr. Ivana Micallef describing the research, are available on the Mayo Clinic News Blog.


'/>"/>
SOURCE Mayo Clinic
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Two targeted therapies likely better than one in patients with aggressive lymphoma
2. Children who view adult-targeted TV may become sexually active earlier in life
3. Targeted agent shows promise in biliary cancer study
4. Targeted Treatments Show Mettle Against Advanced Cancers
5. UCSF, Stanford Study Reveals Neural Networks Targeted in Brain Diseases
6. Adventist Midwest Health Engages Medium Blue Search Engine Marketing in Geographically-Targeted SEO Campaign
7. M. D. Anderson Cancer Center Acquires Leksell Gamma Knife Perfexion for Targeted Brain Lesion Treatments
8. Cancer Researcher Dan Von Hoff, M.D. Advocates for "Context of Vulnerability," A Powerful New Paradigm for Targeted Drug Development
9. Pearly Penile Papule Patients Can Successfully Be Treated with Targeted CO2 Technology at La Jolla Cosmetic Surgery Centre
10. Targeted nanospheres find, penetrate, then fuel burning of melanoma
11. Health Integrated Achieves NCQA Full Accreditation for Its Synergy Targeted Population Management(TM) Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, whether it’s ... setting the bar too high can result in disappointment, perhaps even self-loathing. However, those ... goal. , Research from PsychTests.com reveals that behind the tendency to ...
(Date:6/24/2016)... ... ... in a crisis. Her son James, eight, was out of control. Prone to extreme mood ... something upset him, he couldn’t control his emotions,” remembers Marcy. “If there was a ... children and say he was going to kill them. If we were driving on ...
(Date:6/24/2016)... Diego, CA (PRWEB) , ... June 24, 2016 , ... ... with the American Cancer Society and the Road To Recovery® program to drive cancer ... to seniors and other adults to ensure the highest quality of life and ongoing ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Haute Beauty ... Barry M. Weintraub as a prominent plastic surgeon and the network’s newest partner. ... and the most handsome men, look naturally attractive. Plastic surgery should be invisible.” ...
(Date:6/24/2016)... ... ... Venture Construction Group (VCG) sponsors Luke’s Wings 5th Annual ... Country Club at 1201 Rockville Pike, Rockville, Maryland, 20852. The event raised funds ... been wounded in battle and their families. Venture Construction Group is a 2016 Silver ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... NAMUR , Belgium , ...  (NYSE MKT: VNRX), today announced the appointment of ... Board of Directors as a Non-Executive Director, effective ... the Company,s Audit, Compensation and Nominations and Governance ... Board, Dr. Futcher will provide independent expertise and ...
(Date:6/23/2016)... HILLS, Calif. , June 23, 2016 Any ... the many challenges of the current process. Many of them ... because of the technical difficulties and high laboratory costs involved. ... have to offer it at such a high cost that ... afford it. Dr. Parsa Zadeh , founder ...
(Date:6/23/2016)... Research and Markets has announced the ... 2016 - Forecast to 2022" report to their offering. ... up to date financial data derived from varied research sources ... with potential impact on the market during the next five ... comprises of sub markets, regional and country level analysis. The ...
Breaking Medicine Technology: